These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30115088)

  • 21. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
    Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
    Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
    Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
    Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
    Culp TD; Spatz CM; Reed CA; Christensen ND
    Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of chimeric candidate vaccine against HPV18: a proof of concept.
    Wahiduzzaman M; Sharma C; Dey B; Bhatla N; Singh N
    Immunol Res; 2015 Jun; 62(2):189-97. PubMed ID: 25929429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.
    Kemp TJ; Matsui K; Shelton G; Safaeian M; Pinto LA
    Hum Vaccin Immunother; 2015; 11(2):337-46. PubMed ID: 25695397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
    Seitz H; Ribeiro-Müller L; Canali E; Bolchi A; Tommasino M; Ottonello S; Müller M
    Cancer Prev Res (Phila); 2015 Oct; 8(10):932-41. PubMed ID: 26170394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid.
    Zhang C; Huang X; Chen S; Li Y; Li Y; Wang X; Tang J; Xia L; Lin Z; Luo W; Li T; Li S; Zhang J; Xia N; Zhao Q
    Vaccine; 2018 Oct; 36(45):6761-6771. PubMed ID: 30287156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
    Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
    Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
    Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
    Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
    Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.
    Robbins HA; Li Y; Porras C; Pawlita M; Ghosh A; Rodriguez AC; Schiffman M; Wacholder S; Kemp TJ; Gonzalez P; Schiller J; Lowy D; Esser M; Matys K; Quint W; van Doorn LJ; Herrero R; Pinto LA; Hildesheim A; Waterboer T; Safaeian M
    BMC Infect Dis; 2014 Mar; 14():120. PubMed ID: 24588945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
    Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
    Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli].
    Xie M; Li S; Shen W; Li Z; Zhuang Y; Mo X; Gu Y; Wu T; Zhang J; Xia N
    Sheng Wu Gong Cheng Xue Bao; 2009 Jul; 25(7):1082-7. PubMed ID: 19835152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
    Bishop B; Dasgupta J; Klein M; Garcea RL; Christensen ND; Zhao R; Chen XS
    J Biol Chem; 2007 Oct; 282(43):31803-11. PubMed ID: 17804402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.